Meltwind Advisory LLP

Following his recent receipt of the BioIndustry Association Lifetime Achievement Award, we spoke with our CEO, Jonathan Milner, to reflect on his career as both #entrepreneur and #investor, the key revolutions that have driven the "golden age of #biotechnology", and the exciting companies at the forefront of #innovation in these areas. Read the full interview here: https://rb.gy/ty2mf7 #AI #drugdiscovery #lifescience

I'm thrilled and super excited to be taking on the role of interim CEO of bit.bio starting on January the 6th. Here's the press release

Our founder and Chief Scientific Officer, Prof. Jason Chin, recently spoke with Nature Magazine for its ‘An Audience with…’ series, discussing the role of non-canonical amino acids in synthetic biology.    “The interesting frontier here is how do you generate versions of enzymes that do things that haven't been accessed by natural evolution.” – Prof. Jason Chin    The conversation highlighted critical developments in Constructive’s research and the wider industry, shaping the future of drug production and discovery. As Jason says, the best is yet to come.    Thank you to Asher Mullard for your insightful piece.    #TeamConstructive #SyntheticBiology #Innovation    https://lnkd.in/edmf5c8T

Congratulations to the entire team at Relation on your strategic collaborations with GSK in fibrosis and osteoarthritis!

Join Infinitopes at the Society for Immunotherapy of Cancer (SITC) Annual Meeting today in Houston, where we will be presenting our latest breakthroughs in cancer vaccine discovery and development.   Powered by our AI/ML Precision Immunomics™ antigen discovery platform, we can identify best-in-class pools of hundreds of novel cancer-specific antigens, to empower collaborator’s T-cell & TCR therapies, in addition to our vaccine pipeline. Our lead vaccine candidate ITOP1, is a precision-targeted, immunologically durable, “off-the-shelf” cancer vaccine, designed to prevent recurrence of oesophageal cancer (OC) in patients. ITOP1 has the potential to offer a transformative approach to cancer treatment and will be entering Phase I/IIa clinical development (VISTA study) in H1 '25.    We will be presenting three posters on our pioneering cancer vaccine discovery and development on 8 November, 9am – 7pm CDT:   🔬 Poster #635: ‘A randomised, placebo-controlled, multi-centre Phase I/IIa study evaluating the safety and clinical activity of a novel viral vector cancer vaccine (ITOP1) in patients with resectable oesophageal adenocarcinoma (VISTA study)’ 👩🔬 Poster #1039, recognised as a SITC Top 100 poster: ‘Vaccination with a single dose of a novel delivery platform confers durable >8 month immune responses, with lasting protection against tumour and metastases in preclinical models’ ⚕ Poster #1427: ‘Precision Immunomics™: Identification of hundreds of novel cancer antigens using a sensitive immunopeptidomics-led platform’   Using our integrated ‘right targets, right vectors, right patients, right time’ approach, we are excited to share our latest research as we aim to address unmet clinical need using durably effective therapies to save lives by preventing or significantly delaying disease recurrence for cancer patients.   For more details on our world-leading platforms in precision antigen discovery with vaccine vectors, you can find the full press release on our website and in the comments below.   #Infinitopes #PrecisionMedicine #SITC2024 #Immunotherapy #CancerResearch #CancerVaccine

We’re partnering with Domainex to expand access to our protein production screening capabilities! Many biotechs and startups don’t have their own protein making capabilities. That’s why we’re working with excellent protein CROs like Domainex so that everyone can get the bespoke proteins they need for their discovery projects.

Spirea is delighted to announce that Bo Rode Hansen has joined the company as an Executive Director. Bo brings transformative leadership and strategic insight to Spirea, leveraging over two decades in general management, board roles, R&D, business development, and financing within the biotech and pharmaceutical industries. Bo will lead the Spirea management team to secure the company’s primary position in next-generation ADCs. For more information see: https://lnkd.in/dvR_d58P

Exciting Progress in Rare Disease Treatment at Healx! Proud to share that our lead program, HLX-1502, has received FastTrack designation from the FDA, bringing us one step closer to delivering a breakthrough treatment for neurofibromatosis type 1 (NF1). This designation underscores the urgent need for new therapeutic options in NF1 and accelerates our path to making a real impact for patients and their families. Explore our latest blog to learn more about HLX-1502, what FastTrack means for our team and the NF1 community, and the next steps in our journey. Read more on our website: https://lnkd.in/gjMayGgP #Healx #RareDisease #NF1 #FastTrack #Biotech #FDA

Today we have announced a strategic collaboration with Eli Lilly and Company to develop novel genetic medicines using our polyNaut® platform: https://lnkd.in/eH7Qh53F This marks a significant step forward in leveraging our polyNaut® nanovesicle platform, designed to precisely target specific tissues and cell types, even in hard-to-reach areas such as the central nervous system. With its ability to efficiently deliver genetic cargoes, polyNaut® has the potential to transform genetic nanomedicine delivery and address significant unmet needs. #ViaNautis #polyNaut #Lilly #Biotech #Nanomedicine

Very happy to announce that ViaNautis and Eli Lilly have signed a collaboration and licence agreement. https://lnkd.in/eH7Qh53F This is a huge milestone in advancing polynaut as targeted nanomedicines for patients that have few options. A big thank you to all involved in reaching this important point including the Lilly team who we are greatly looking forward to working with in productive partnership. #vianautis #polynaut #Lilly #nanomedicine